144927-57-1

Basic information

• Product Name: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
• Synonyms: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate;3-d]pyriMidine-5-carboxylate;ethyl 4-chloro-7H-pyrrolo[2;Ethyl 4-chloro-7H-pyrrolo...;ethyl 4-chloro-1H-pyrrolo[2,3-d]pyrimidine-5-carboxylate
• CAS NO: 144927-57-1
• Molecular Formula: C₉H₈ClN₃O₂
• Molecular Weight: 225.63172
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyrimidine series
• Mol File: 144927-57-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 140-141 °C
• Boiling Point: 397.056 °C at 760 mmHg
• Flash Point: 193.933 °C
• Appearance: /
• Density: 1.459 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.644
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.72±0.20(Predicted)
• CAS DataBase Reference: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(144927-57-1)
• EPA Substance Registry System: ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate(144927-57-1)

Safety Data

• Hazardous Substances Data: 144927-57-1(Hazardous Substances Data)

Usage

General Description

Ethyl 4-chloro-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate is a chemical compound with an ethyl group attached to a pyrrolopyrimidine ring. The compound also contains a chloro group and a carboxylate group. It has potential applications in the field of medicinal chemistry and drug discovery, as it may serve as a building block for the synthesis of new pharmaceutical compounds. Its structure suggests that it may have biological activity and could be used as a starting point for the development of new drugs targeting specific cellular pathways. Further research and testing of this compound may reveal its potential uses in the pharmaceutical industry.

InChI:InChI=1/C9H8ClN3O2/c1-2-15-9(14)5-3-11-8-6(5)7(10)12-4-13-8/h3-4H,2H2,1H3,(H,11,12,13)

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 1443234-98-7 3-[5-(ethoxycarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzoic acid 
• 1443237-43-1 ethyl 4-(3-nitrophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443234-82-9 ethyl 4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443237-57-7 ethyl 4-(3-(methylamino)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-90-5 ethyl 4-(3-(N-methylacrylamido)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443234-84-1 ethyl 4-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443236-94-9 ethyl 4-(3-((2-(fluoromethyl)acryloyl)amino)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate 
• 1443238-06-9 3-(5-(oxazol-5-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aniline 
• 1443238-05-8 5-(4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)oxazole 
• 1443238-04-7 4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbaldehyde 
• 1443238-03-6 N-methoxy-N-methyl 4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 
• 1443237-94-2 N-(2-hydroxypropyl)-4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 
• 1443237-92-0 3-(5-(5-methyl-1,3,4-thiadiazol-2-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)aniline 
• 1443237-91-9 2-methyl-5-(4-(3-nitrophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1,3,4-thiadiazole 

Relevant articles and documents

PYRROLOPYRIMIDINES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of formula I which are JAK3 inhibitors. Specifically, the compounds of formula I are pyrrolo[2,3-d]pyrimidine derivative compounds. The instant invention also provides methods of treating JAK-mediated diseases such

Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues

Adenosine receptor agonists produce a wide variety of therapeutically useful pharmacologies. However, to date they have failed to undergo successful clinical development due to dose-limiting side effects. Adenosine kinase inhibitors (AKIs) represent an alternative strategy, since AKIs may raise local adenosine levels in a more site- and event-specific manner and thereby elicit the desired pharmacology with a greater therapeutic window. Starting with 5-iodotubercidin (IC50 = 0.026 μM) and 5'-amino-5'- deoxyadenosine (IC50 = 0.17 μM) as lead inhibitors of the isolated human AK, a variety of pyrrolo[2,3-d]pyrimidine nucleoside analogues were designed and prepared by coupling 5-substituted-4-chloropyrrolo[2,3-d]pyrimidine bases with ribose analogues using the sodium salt-mediated glycosylation procedure. 5'-Amino-5'-deoxy analogues of 5-bromo- and 5-iodotubercidins were found to be the most potent AKIs reported to date (IC50s 0.001 μM). Several potent AKIs were shown to exhibit anticonvulsant activity in the rat maximal electric shock (MES) induced seizure assay.